Connect
MJA
MJA

Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory

James M Trauer and Vicki L Krause
Med J Aust 2011; 194 (11): 579-582.

Summary

Objectives: To assess the prevalence of latent tuberculosis infection (LTBI) in recently arrived refugees in the Northern Territory and to obtain comprehensive data for rates of treatment acceptance and completion for this condition.

Design, setting and participants: Prospective data collection and follow-up of all 471 newly arrived refugees seen at the Centre for Disease Control, NT refugee health clinic from February 2006 to January 2009.

Main outcome measures: Rates of LTBI determined by tuberculin skin testing; subsequent assessment and treatment compared with local protocols.

Results: 458 of 465 eligible refugees were adequately assessed for LTBI, of whom 146 (31.9%) were diagnosed with LTBI. Older age, male sex and World Health Organization Eastern Mediterranean region of birth were associated with increased prevalences of LTBI. Of the refugees diagnosed with LTBI, 10 failed to attend for follow-up and 15 were not offered treatment. Isoniazid therapy was accepted by 93 of 121 refugees (76.9%), and 41 of these (44.1%) completed treatment. The most common reasons for discontinuation of therapy were medication-related side effects (most often gastrointestinal) and loss to follow-up. Increasing age was associated with failure to complete treatment.

Conclusion: Outcomes of assessment and treatment for LTBI in newly arrived refugees in the NT are comparable to those for other target groups screened in developed countries. Loss to follow-up caused significant attrition in numbers, but complete data were obtained for a large proportion of eligible refugees. Most refugees who are offered treatment for LTBI accept, but less than half complete treatment.

  • James M Trauer1
  • Vicki L Krause2

  • Centre for Disease Control, Darwin, NT.


Acknowledgements: 

We gratefully acknowledge all CDC-NT staff involved in this ongoing project since 2006. Particular thanks go to Natalie Gray, Lynette Kerr, Julie Graham, Kerryn Coleman and Meredith Hansen-Knarhoi.

Competing interests:

None identified.

  • 1. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010–2050: cure, care, and social development. Lancet 2010; 375: 1814-1829.
  • 2. Al-Orainey IO. Diagnosis of latent tuberculosis: can we do better? Ann Thorac Med 2009; 4: 5-9.
  • 3. Smieja MJ, Marchett CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; (2): CD001363.
  • 4. Moulding T. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 2000; 4: 485-487.
  • 5. Horsburgh CR. Priorities for the treatment of latent tuberculosis in the United States. N Engl J Med 2004; 350: 2060-2067.
  • 6. Centre for Disease Control. Guidelines for the control of tuberculosis in the Northern Territory. 4th ed. Darwin: Northern Territory Government Department of Health and Community Services, 2008.
  • 7. Arshad S, Bavan L, Gajari K, et al. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2010; 35: 1336-1345.
  • 8. Vynnycky E, Borgdorff MW, Leung CC, et al. Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease. Epidemiol Infect 2008; 136: 943-952.
  • 9. Victorian Government Department of Human Services. Management, control and prevention of tuberculosis: guidelines for health care providers 2002–2005. Melbourne: DoHS, 2002. http://www.health.vic.gov.au/__data/assets/pdf_file/0006/19986/tb_mgmt_guide.pdf (accessed Oct 2009).
  • 10. Marks GB, Bai J, Simpson SE, et al. Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med 2000; 162: 1851-1854.
  • 11. Sterling TR, Bethel J, Goldberg S, et al; Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173: 927-931.
  • 12. Coker R, Bell A, Pitman R, et al. Tuberculosis screening in migrants in selected European countries shows wide disparities. Eur Respir J 2006; 27: 801-807.
  • 13. Tiong AC, Patel MS, Gardiner J, et al. Health issues in newly arrived African refugees attending general practice clinics in Melbourne. Med J Aust 2006; 185: 602-606.
  • 14. Lucas M, Nicol P, McKinnon E, et al. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 2010; 65: 442-448.
  • 15. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. Geneva: WHO Press, 2009.
  • 16. World Health Organization. TB profile: Somalia. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG 2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=SO&outtype=pdf (accessed May 2011).
  • 17. World Health Organization. TB profile: Sudan. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2 %2FPROD%2FEXT%2FTBCountryProfile&ISO2=SD&outtype=pdf (accessed May 2011).
  • 18. Horsburgh CR Jr, Goldberg S, Bethel J, et al; Tuberculosis Epidemiologic Studies Consortium. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401-409.
  • 19. Parsyan AE, Saukkonen J, Barry MA, et al. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54: 262-266.
  • 20. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443.
  • 21. Li J, Munsiff SS, Tarantino T, et al. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010; 14: e292-e297.
  • 22. Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008; 12: 1235-1254.
  • 23. Levesque JF, Dongier P, Brassard P, et al. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8: 711-717.
  • 24. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4: e238.
  • 25. Goldberg SV, Wallace J, Jackson JC, et al. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004; 8: 76-82.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.